The Global Oncology Biopharmaceuticals Market was valued at USD 130.6 billion in 2024 and is estimated to grow at a CAGR of 7.5% to reach USD 268.3 billion by 2034.
The market is witnessing a transformative phase driven by the growing worldwide incidence of cancer and the rising need for personalized and targeted treatment solutions. Continuous breakthroughs in next-generation sequencing, immunotherapy, and AI-powered drug development are reshaping how cancer is treated and detected. Over the past year, new treatment innovations and improved access to advanced biologics have redefined therapeutic standards for both hematologic and solid tumors. Precision oncology technologies are enhancing early diagnosis and individualizing treatments to improve patient survival. Market expansion is supported by favorable government programs, higher healthcare investments, and evolving regulatory pathways. The oncology biopharmaceuticals sector continues to lead the shift toward precision medicine by customizing therapies according to each patient’s molecular profile. The industry’s growth is further supported by advancements in biologics, immunotherapies, and the increasing adoption of precision-based medical practices to address the urgent need for more effective cancer management worldwide.
The monoclonal antibodies segment held a 37.6% share in 2024 and is anticipated to reach USD 96 billion by 2034, growing at a CAGR of 7%. Monoclonal antibodies remain a cornerstone of contemporary oncology, as they are highly specific biologic agents that bind to unique antigens expressed on cancer cells. These targeted therapies work by directly attacking tumor cells, interrupting tumor growth signaling, and stimulating immune activity to eliminate cancerous tissues. Compared to conventional chemotherapy, monoclonal antibodies offer a more favorable safety profile, minimizing off-target effects and enhancing treatment precision.
The lung cancer application segment generated USD 37.5 billion in 2024. Lung cancer remains the most fatal cancer type globally, with non-small cell lung cancer (NSCLC) accounting for nearly 85% of all cases. The market has experienced a major transformation due to the growing availability of precision-based and immuno-oncology treatments. Modern therapeutic advancements focused on specific genetic and molecular targets have significantly improved patient outcomes and treatment success rates.
U.S. Oncology Biopharmaceuticals Market reached USD 51.9 billion in 2024. Technological progress in artificial intelligence is revolutionizing cancer diagnostics and accelerating the development of next-generation oncology drugs. However, unequal access to these advanced treatments remains a persistent challenge, particularly among underrepresented groups. The U.S. continues to make strides in advancing biosimilars and personalized therapies, with strong investments aimed at improving affordability and enhancing patient access to cell-based and immune therapies.
Key participants in the Oncology Biopharmaceuticals Market include AbbVie, Amgen, AstraZeneca, Bayer, Biogen, Bristol-Myers Squibb, Eli Lilly, F. Hoffmann-La Roche, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Sanofi, Takeda Pharmaceutical, Sandoz, Biocon, Celltrion, Adaptimmune, Legend Biotech, and Arcellx. To reinforce their position in the Global Oncology Biopharmaceuticals Market, major companies are focusing on strategic collaborations, mergers, and acquisitions to broaden their oncology pipelines and accelerate drug development. Firms are expanding their research partnerships with biotech innovators to co-develop targeted biologics and immunotherapies. Investment in advanced technologies such as AI, genomics, and molecular profiling is being prioritized to strengthen precision medicine capabilities. Companies are also working toward regulatory alignment to speed up product approvals and expand geographic reach.
This product will be delivered within 2-4 business days.
The market is witnessing a transformative phase driven by the growing worldwide incidence of cancer and the rising need for personalized and targeted treatment solutions. Continuous breakthroughs in next-generation sequencing, immunotherapy, and AI-powered drug development are reshaping how cancer is treated and detected. Over the past year, new treatment innovations and improved access to advanced biologics have redefined therapeutic standards for both hematologic and solid tumors. Precision oncology technologies are enhancing early diagnosis and individualizing treatments to improve patient survival. Market expansion is supported by favorable government programs, higher healthcare investments, and evolving regulatory pathways. The oncology biopharmaceuticals sector continues to lead the shift toward precision medicine by customizing therapies according to each patient’s molecular profile. The industry’s growth is further supported by advancements in biologics, immunotherapies, and the increasing adoption of precision-based medical practices to address the urgent need for more effective cancer management worldwide.
The monoclonal antibodies segment held a 37.6% share in 2024 and is anticipated to reach USD 96 billion by 2034, growing at a CAGR of 7%. Monoclonal antibodies remain a cornerstone of contemporary oncology, as they are highly specific biologic agents that bind to unique antigens expressed on cancer cells. These targeted therapies work by directly attacking tumor cells, interrupting tumor growth signaling, and stimulating immune activity to eliminate cancerous tissues. Compared to conventional chemotherapy, monoclonal antibodies offer a more favorable safety profile, minimizing off-target effects and enhancing treatment precision.
The lung cancer application segment generated USD 37.5 billion in 2024. Lung cancer remains the most fatal cancer type globally, with non-small cell lung cancer (NSCLC) accounting for nearly 85% of all cases. The market has experienced a major transformation due to the growing availability of precision-based and immuno-oncology treatments. Modern therapeutic advancements focused on specific genetic and molecular targets have significantly improved patient outcomes and treatment success rates.
U.S. Oncology Biopharmaceuticals Market reached USD 51.9 billion in 2024. Technological progress in artificial intelligence is revolutionizing cancer diagnostics and accelerating the development of next-generation oncology drugs. However, unequal access to these advanced treatments remains a persistent challenge, particularly among underrepresented groups. The U.S. continues to make strides in advancing biosimilars and personalized therapies, with strong investments aimed at improving affordability and enhancing patient access to cell-based and immune therapies.
Key participants in the Oncology Biopharmaceuticals Market include AbbVie, Amgen, AstraZeneca, Bayer, Biogen, Bristol-Myers Squibb, Eli Lilly, F. Hoffmann-La Roche, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Sanofi, Takeda Pharmaceutical, Sandoz, Biocon, Celltrion, Adaptimmune, Legend Biotech, and Arcellx. To reinforce their position in the Global Oncology Biopharmaceuticals Market, major companies are focusing on strategic collaborations, mergers, and acquisitions to broaden their oncology pipelines and accelerate drug development. Firms are expanding their research partnerships with biotech innovators to co-develop targeted biologics and immunotherapies. Investment in advanced technologies such as AI, genomics, and molecular profiling is being prioritized to strengthen precision medicine capabilities. Companies are also working toward regulatory alignment to speed up product approvals and expand geographic reach.
Comprehensive Market Analysis and Forecast
- Industry trends, key growth drivers, challenges, future opportunities, and regulatory landscape
- Competitive landscape with Porter’s Five Forces and PESTEL analysis
- Market size, segmentation, and regional forecasts
- In-depth company profiles, business strategies, financial insights, and SWOT analysis
This product will be delivered within 2-4 business days.
Table of Contents
Chapter 1 Methodology and Scope
Chapter 2 Executive Summary
Chapter 3 Industry Insights
Chapter 4 Competitive Landscape, 2024
Chapter 5 Market Estimates and Forecast, by Product Type, 2021-2034 ($ Bn)
Chapter 6 Market Estimates and Forecast, by Cancer Type, 2021-2034 ($ Bn)
Chapter 7 Market Estimates and Forecast, by Route of Administration, 2021-2034 ($ Bn)
Chapter 8 Market Estimates and Forecast, by Drug Type, 2021-2034 ($ Bn)
Chapter 9 Market Estimates and Forecast, by Distribution Channel, 2021-2034 ($ Bn)
Chapter 10 Market Estimates and Forecast, by Region, 2021-2034 ($ Bn)
Chapter 11 Company Profiles
Companies Mentioned
The companies profiled in this Oncology Biopharmaceuticals market report include:- AbbVie
- Amgen
- AstraZeneca
- Bayer
- Biogen
- Bristol-Myers Squibb
- Eli Lilly
- F. Hoffmann-La Roche
- GlaxoSmithKline
- Johnson & Johnson
- Merck
- Novartis
- Pfizer
- Sanofi
- Takeda Pharmaceutical
- Sandoz
- Biocon
- Celltrion
- Adaptimmune
- Legend Biotech
- Arcellx
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 140 |
| Published | October 2025 |
| Forecast Period | 2024 - 2034 |
| Estimated Market Value ( USD | $ 130.6 Billion |
| Forecasted Market Value ( USD | $ 268.3 Billion |
| Compound Annual Growth Rate | 7.5% |
| Regions Covered | Global |
| No. of Companies Mentioned | 22 |
